Thomas P. Fondy . Professor Cancer chemotherapeutic drug development tpfondy@syr.edu Office: 302 Biological Research Labs (BRL) Phone: 315-443-2615 / fax: 315-443-2012 Education: • Ph.D., Duquesne University, 1961 • Postdoc, Brandeis University, 1962-1965 Courses: • BIO 215: Biology, Medicine and Human Values • BIO 325: Cell Biology • BIO 447: Immunobiology • BIO 501: Biology of Cancer • BIO 547: Immunology: Applications to Research and Medicine

RESEARCH

Dr. Fondy's personal website at Syracuse University: http://syllabus.syr.edu/BIO/tpfondy/tpfinfo2002.htm

SELECTED PUBLICATIONS:

Biostent (Cytochalasin B) in the Prevention of Arterial Restenosis after Coronary Artery Balloon Angioplasty. Investigational New Drug Application, Filed: December, 1994.

Patterns of Resistance to Cytochalasins in Drug Sensitive and Multidrug Resistant Human Ovarian Carcinoma and Murine Leukemia Lines. Thomas P. Fondy. General Motors Cancer Research Foundation International Symposium, Toronto, Canada, 1993 (Abstract).

Cytochalasin B -Induced Immunosuppression of Murine Allogeneic Anti-Tumor Response and the Effect of Recombinant Human Interleukin-2. Dennis Bogyo, Susan R.E. Fondy, Luanne Finster, Christopher Fondy, Sheila Patil, and Thomas P. Fondy. Cancer Immunology and Immunotherapy, 32: 400-405 (1991).

Effects of Cytochalasin B in Culture and In Vivo on Murine Madison 109 Lung Carcinoma and on B16 Melanoma. Peter F. Bousquet, Lesa A. Paulsen, Christopher Fondy, Karen M. Lipski, Karen J. Loucy, and Thomas P. Fondy. Cancer Research , 50:1431-1439 (1990).